PedAM
Pediatric Disease Annotations & Medicines
| hydrocephalus | ||||
| Disease ID | 180 |
|---|---|
| Disease | hydrocephalus |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:83) C2707258 | infections C2632116 | stenosis C2364324 | increased intracranial pressure C2096315 | headache C2096314 | facial pain C2029884 | hearing loss C2020541 | strabismus C1997217 | low-grade glioma C1963138 | hypertension C1963101 | encephalopathy C1527311 | brain edema C1455718 | ventriculitis C1442871 | craniosynostosis C1421317 | urofacial syndrome C1416776 | congenital muscular dystrophy C1336049 | sarcoma of the spinal cord C1276004 | bilateral trochlear nerve paresis C1141920 | shunt infection C0854912 | pineal germinoma C0796110 | w syndrome C0796095 | c syndrome C0746408 | mass lesion C0547030 | visual disturbance C0520731 | retraction nystagmus C0497327 | dementia C0426768 | o sign C0422833 | ent symptoms C0346308 | pituitary macroadenoma C0340098 | neurogenic pulmonary edema C0338591 | transient global amnesia C0271885 | hypothalamic obesity C0266484 | schizencephaly C0265292 | craniometaphyseal dysplasia C0264733 | ventricular dilatation C0262471 | ent problem C0242567 | opsoclonus C0242422 | parkinsonism C0242422 | parkinsonian syndromes C0238074 | chronic cor pulmonale C0232940 | secondary amenorrhea C0221355 | macrocephaly C0206733 | capillary hemangioma C0205770 | choroid plexus papilloma C0162429 | undernutrition C0158534 | spina bifida C0152222 | parinaud's syndrome C0152134 | internuclear ophthalmoplegia C0151740 | raised intracranial pressure C0151740 | intracranial hypertension C0151740 | elevated intracranial pressure C0149931 | migraine C0086543 | cataracts C0078981 | arachnoid cyst C0042928 | vocal cord paralysis C0041408 | turner syndrome C0039145 | syringomyelia C0037939 | spinal tumors C0036454 | visual field defects C0036454 | visual field defect C0030354 | papilloma C0030167 | pachymeningitis C0027831 | von recklinghausen's disease C0027809 | neurinoma C0027765 | neurological disorder C0026650 | dyskinesia syndrome C0025289 | meningitis C0024299 | malignant lymphoma C0022521 | immotile cilia syndrome C0020635 | hypopituitarism C0019570 | hirschsprung's disease C0018920 | cavernous hemangioma C0018681 | headaches C0017638 | gliomas C0014544 | epilepsy C0014306 | enophthalmos C0014038 | encephalitis C0013604 | oedema C0010678 | cysticercosis C0010278 | craniostenosis C0008780 | ciliary dyskinesia C0007815 | cerebrospinal fluid rhinorrhea C0007684 | central nervous system infections C0006118 | brain tumors |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:27) C0025289 | meningitis | 25 C0009814 | stenosis | 15 C0151740 | increased intracranial pressure | 12 C0151740 | intracranial hypertension | 10 C0080178 | spina bifida | 8 C0020538 | hypertension | 7 C0078981 | arachnoid cyst | 6 C0151740 | raised intracranial pressure | 6 C0018681 | headache | 5 C0221355 | macrocephaly | 5 C0302598 | ventriculitis | 4 C0017638 | gliomas | 3 C0039144 | syringomyelia | 3 C0151740 | elevated intracranial pressure | 3 C0013604 | oedema | 3 C0010278 | craniosynostosis | 3 C0018681 | headaches | 2 C1141920 | shunt infection | 2 C0264733 | ventricular dilatation | 2 C0497327 | dementia | 2 C0426768 | o sign | 2 C0014544 | epilepsy | 2 C0205770 | choroid plexus papilloma | 1 C0006118 | brain tumors | 1 C0020635 | hypopituitarism | 1 C0085666 | capillary hemangioma | 1 C0008780 | ciliary dyskinesia | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs369384363 | NA | 440193 | CCDC88C | umls:C0020255 | CLINVAR | NA | 0.12 | NA | CCDC88C | 14 | 91338121 | G | A,C |
| rs387906597 | 21340693 | 652 | BMP4 | umls:C0020255 | BeFree | A patient with anophthalmia, microphthalmia with sclerocornea, right-sided diaphragmatic hernia, and hydrocephalus was found to have a c.592C >T (p.R198X) nonsense mutation in BMP4. | 0.000271442 | 2011 | BMP4 | 14 | 53950667 | G | C,A |
| rs387907320 | NA | 440193 | CCDC88C | umls:C0020255 | CLINVAR | NA | 0.12 | NA | CCDC88C | 14 | 91277921 | C | T |
| rs387907321 | NA | 440193 | CCDC88C | umls:C0020255 | CLINVAR | NA | 0.12 | NA | CCDC88C | 14 | 91272870 | CT | - |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:11) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0020255 | aminocaproic acid | D015119 | 60-32-2 | hydrocephalus | MESH:D006849 | marker/mechanism | 20881558 | ||
| C0020255 | caffeine | D002110 | 1958/8/2 | hydrocephalus | MESH:D006849 | marker/mechanism | 5041373 | ||
| C0020255 | carmustine | D002330 | 154-93-8 | hydrocephalus | MESH:D006849 | marker/mechanism | 17334672 | ||
| C0020255 | chloramphenicol | D002701 | 56-75-7 | hydrocephalus | MESH:D006849 | marker/mechanism | 2041948 | ||
| C0020255 | folic acid | D005492 | 59-30-3 | hydrocephalus | MESH:D006849 | marker/mechanism | 14324085 | ||
| C0020255 | linezolid | D000069349 | - | hydrocephalus | MESH:D006849 | therapeutic | 18622679 | ||
| C0020255 | methadone | D008691 | 76-99-3 | hydrocephalus | MESH:D006849 | marker/mechanism | 16997682 | ||
| C0020255 | oxycodone | D010098 | 76-42-6 | hydrocephalus | MESH:D006849 | marker/mechanism | 20440598 | ||
| C0020255 | tretinoin | D014212 | 302-79-4 | hydrocephalus | MESH:D006849 | marker/mechanism | 1438063 | ||
| C0020255 | valproic acid | D014635 | 99-66-1 | hydrocephalus | MESH:D006849 | marker/mechanism | 12237071 | ||
| C0020255 | vitamin a | D014801 | 11103-57-4 | hydrocephalus | MESH:D006849 | marker/mechanism | 13410607 | ||
FDA approved drug and dosage information(Total Drugs:6) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D006849 | zyvox | linezolid | 400MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | TABLET;ORAL | Discontinued | None | Yes | No |
| MESH:D006849 | zyvox | linezolid | 200MG/100ML (2MG/ML) | SOLUTION;IV (INFUSION) | Prescription | AP | Yes | No |
| MESH:D006849 | zyvox | linezolid | 100MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | Yes |
| MESH:D006849 | zyvox | linezolid | 400MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | TABLET;ORAL | Discontinued | None | Yes | No |
| MESH:D006849 | zyvox | linezolid | 200MG/100ML (2MG/ML) | SOLUTION;IV (INFUSION) | Prescription | AP | Yes | No |
| MESH:D006849 | zyvox | linezolid | 100MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | Yes |
FDA labeling changes(Total Drugs:6) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D006849 | 12/19/2002 | zyvox | linezolid | Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains | Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies | Labeling | B | - | - | - | Pfizer | 11/2/2005 | FALSE' |
| MESH:D006849 | 12/19/2002 | zyvox | linezolid | Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains | Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies | Labeling | B | - | - | - | Pfizer | 11/2/2005 | FALSE' |
| MESH:D006849 | 12/19/2002 | zyvox | linezolid | Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains | Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies | Labeling | B | - | - | - | Pfizer | 11/2/2005 | FALSE' |
| MESH:D006849 | 12/5/2005 | zyvox | linezolid | Central nervous system infections | PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium | Labeling | B | - | - | - | Pfizer | 11/2/2005 | FALSE' |
| MESH:D006849 | 12/5/2005 | zyvox | linezolid | Central nervous system infections | PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium | Labeling | B | - | - | - | Pfizer | 11/2/2005 | FALSE' |
| MESH:D006849 | 12/5/2005 | zyvox | linezolid | Central nervous system infections | PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium | Labeling | B | - | - | - | Pfizer | 11/2/2005 | FALSE' |